APA (7th ed.) Citation

Burstein, A. H., Brantley, S. J., Dunn, I., Altstiel, L. D., & Schmith, V. (2019). Assessment of Azeliragon QTc Liability Through Integrated, Model‐Based Concentration QTc Analysis. Clinical Pharmacology in Drug Development, 8(4), 426. https://doi.org/10.1002/cpdd.689

Chicago Style (17th ed.) Citation

Burstein, Aaron H., Scott J. Brantley, Imogene Dunn, Larry D. Altstiel, and Virginia Schmith. "Assessment of Azeliragon QTc Liability Through Integrated, Model‐Based Concentration QTc Analysis." Clinical Pharmacology in Drug Development 8, no. 4 (2019): 426. https://doi.org/10.1002/cpdd.689.

MLA (9th ed.) Citation

Burstein, Aaron H., et al. "Assessment of Azeliragon QTc Liability Through Integrated, Model‐Based Concentration QTc Analysis." Clinical Pharmacology in Drug Development, vol. 8, no. 4, 2019, p. 426, https://doi.org/10.1002/cpdd.689.